Management of Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medic...
Gespeichert in:
| Veröffentlicht in: | Annual review of medicine 2016-01, Vol.67 (1), p.137-151 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | 1 |
| container_start_page | 137 |
| container_title | Annual review of medicine |
| container_volume | 67 |
| creator | Kim, Eric H Larson, Jeffrey A Andriole, Gerald L |
| description | Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medical history and focused physical examination, with attention to other conditions that may be causing LUTS. Digital rectal examination and urinalysis should be performed. Other testing may be considered depending on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethroscopy, post-void residual, and pressure-flow studies. Many medical and surgical treatment options exist. Surgery should be reserved for patients who either have failed medical management or have complications from BPH, such as recurrent urinary tract infections, refractory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy. |
| doi_str_mv | 10.1146/annurev-med-063014-123902 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_26331999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3967386571</sourcerecordid><originalsourceid>FETCH-LOGICAL-a451t-1aab28da2e5bc20916a8f74bff455adfa179adb761f053cf72963d664d6786333</originalsourceid><addsrcrecordid>eNqVkE1LxDAQhoMo7rr6F6TiRYRqPpq0uQi6-AUrelDwFqZtsnRp0zVplf33pnT34s3THOaZd2YehM4IviIkEddgbe_0d9zoMsaCYZLEhDKJ6R6aEp7wmFHxuY-mGAsRJ5TICTryfoUxloxlh2hCBWNESjlFly9gYakbbbuoNdGdttXSRm-u9R10VRE9bdbarWvwFRyjAwO11yfbOkMfD_fv86d48fr4PL9dxJBw0sUEIKdZCVTzvKBYEgGZSZPcmIRzKA2QVEKZp4IYzFlhUioFK4VISpFm4S42Qxdj7tq1X732nWoqX-i6Bqvb3iuSCpxlKac4oOd_0FXbOxuuG6hMYp7yIVCOVBHe8k4btXZVA26jCFaDULUVqoJQNQpVo9Awe7rd0OdDdze5MxiAmxEYMqAOKZX-8f_Y8Avfb4gp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768905753</pqid></control><display><type>article</type><title>Management of Benign Prostatic Hyperplasia</title><source>Annual Reviews Complete A-Z List</source><source>MEDLINE</source><creator>Kim, Eric H ; Larson, Jeffrey A ; Andriole, Gerald L</creator><creatorcontrib>Kim, Eric H ; Larson, Jeffrey A ; Andriole, Gerald L</creatorcontrib><description>Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medical history and focused physical examination, with attention to other conditions that may be causing LUTS. Digital rectal examination and urinalysis should be performed. Other testing may be considered depending on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethroscopy, post-void residual, and pressure-flow studies. Many medical and surgical treatment options exist. Surgery should be reserved for patients who either have failed medical management or have complications from BPH, such as recurrent urinary tract infections, refractory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy.</description><identifier>ISSN: 0066-4219</identifier><identifier>EISSN: 1545-326X</identifier><identifier>DOI: 10.1146/annurev-med-063014-123902</identifier><identifier>PMID: 26331999</identifier><language>eng</language><publisher>United States: Annual Reviews</publisher><subject>5-alpha reductase inhibitors ; 5-alpha Reductase Inhibitors - therapeutic use ; Ablation Techniques ; adrenergic alpha-antagonists ; Adrenergic alpha-Antagonists - therapeutic use ; Digital Rectal Examination ; Family medical history ; Humans ; Inflammation ; Laser Therapy ; lower urinary tract symptoms ; Lower Urinary Tract Symptoms - etiology ; Male ; Medical diagnosis ; Phosphodiesterase 5 Inhibitors - therapeutic use ; phosphodiesterase type 5 inhibitors ; Prostatic Hyperplasia - complications ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - metabolism ; Prostatic Hyperplasia - pathology ; Prostatic Hyperplasia - therapy ; Transurethral Resection of Prostate ; Urinalysis ; Urinary tract diseases ; Watchful Waiting</subject><ispartof>Annual review of medicine, 2016-01, Vol.67 (1), p.137-151</ispartof><rights>Copyright © 2016 by Annual Reviews. All rights reserved 2016</rights><rights>Copyright Annual Reviews, Inc. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a451t-1aab28da2e5bc20916a8f74bff455adfa179adb761f053cf72963d664d6786333</citedby><cites>FETCH-LOGICAL-a451t-1aab28da2e5bc20916a8f74bff455adfa179adb761f053cf72963d664d6786333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-med-063014-123902?crawler=true&mimetype=application/pdf$$EPDF$$P50$$Gannualreviews$$H</linktopdf><linktohtml>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-med-063014-123902$$EHTML$$P50$$Gannualreviews$$H</linktohtml><link.rule.ids>70,314,776,780,4168,27901,27902,77996,77997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26331999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Eric H</creatorcontrib><creatorcontrib>Larson, Jeffrey A</creatorcontrib><creatorcontrib>Andriole, Gerald L</creatorcontrib><title>Management of Benign Prostatic Hyperplasia</title><title>Annual review of medicine</title><addtitle>Annu Rev Med</addtitle><description>Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medical history and focused physical examination, with attention to other conditions that may be causing LUTS. Digital rectal examination and urinalysis should be performed. Other testing may be considered depending on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethroscopy, post-void residual, and pressure-flow studies. Many medical and surgical treatment options exist. Surgery should be reserved for patients who either have failed medical management or have complications from BPH, such as recurrent urinary tract infections, refractory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy.</description><subject>5-alpha reductase inhibitors</subject><subject>5-alpha Reductase Inhibitors - therapeutic use</subject><subject>Ablation Techniques</subject><subject>adrenergic alpha-antagonists</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Digital Rectal Examination</subject><subject>Family medical history</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Laser Therapy</subject><subject>lower urinary tract symptoms</subject><subject>Lower Urinary Tract Symptoms - etiology</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Phosphodiesterase 5 Inhibitors - therapeutic use</subject><subject>phosphodiesterase type 5 inhibitors</subject><subject>Prostatic Hyperplasia - complications</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - metabolism</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Hyperplasia - therapy</subject><subject>Transurethral Resection of Prostate</subject><subject>Urinalysis</subject><subject>Urinary tract diseases</subject><subject>Watchful Waiting</subject><issn>0066-4219</issn><issn>1545-326X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE1LxDAQhoMo7rr6F6TiRYRqPpq0uQi6-AUrelDwFqZtsnRp0zVplf33pnT34s3THOaZd2YehM4IviIkEddgbe_0d9zoMsaCYZLEhDKJ6R6aEp7wmFHxuY-mGAsRJ5TICTryfoUxloxlh2hCBWNESjlFly9gYakbbbuoNdGdttXSRm-u9R10VRE9bdbarWvwFRyjAwO11yfbOkMfD_fv86d48fr4PL9dxJBw0sUEIKdZCVTzvKBYEgGZSZPcmIRzKA2QVEKZp4IYzFlhUioFK4VISpFm4S42Qxdj7tq1X732nWoqX-i6Bqvb3iuSCpxlKac4oOd_0FXbOxuuG6hMYp7yIVCOVBHe8k4btXZVA26jCFaDULUVqoJQNQpVo9Awe7rd0OdDdze5MxiAmxEYMqAOKZX-8f_Y8Avfb4gp</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Kim, Eric H</creator><creator>Larson, Jeffrey A</creator><creator>Andriole, Gerald L</creator><general>Annual Reviews</general><general>Annual Reviews, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Management of Benign Prostatic Hyperplasia</title><author>Kim, Eric H ; Larson, Jeffrey A ; Andriole, Gerald L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a451t-1aab28da2e5bc20916a8f74bff455adfa179adb761f053cf72963d664d6786333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>5-alpha reductase inhibitors</topic><topic>5-alpha Reductase Inhibitors - therapeutic use</topic><topic>Ablation Techniques</topic><topic>adrenergic alpha-antagonists</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Digital Rectal Examination</topic><topic>Family medical history</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Laser Therapy</topic><topic>lower urinary tract symptoms</topic><topic>Lower Urinary Tract Symptoms - etiology</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Phosphodiesterase 5 Inhibitors - therapeutic use</topic><topic>phosphodiesterase type 5 inhibitors</topic><topic>Prostatic Hyperplasia - complications</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - metabolism</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Hyperplasia - therapy</topic><topic>Transurethral Resection of Prostate</topic><topic>Urinalysis</topic><topic>Urinary tract diseases</topic><topic>Watchful Waiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Eric H</creatorcontrib><creatorcontrib>Larson, Jeffrey A</creatorcontrib><creatorcontrib>Andriole, Gerald L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annual review of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Eric H</au><au>Larson, Jeffrey A</au><au>Andriole, Gerald L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Benign Prostatic Hyperplasia</atitle><jtitle>Annual review of medicine</jtitle><addtitle>Annu Rev Med</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>67</volume><issue>1</issue><spage>137</spage><epage>151</epage><pages>137-151</pages><issn>0066-4219</issn><eissn>1545-326X</eissn><abstract>Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development. The diagnosis of BPH hinges on a thorough medical history and focused physical examination, with attention to other conditions that may be causing LUTS. Digital rectal examination and urinalysis should be performed. Other testing may be considered depending on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytology, imaging, cystourethroscopy, post-void residual, and pressure-flow studies. Many medical and surgical treatment options exist. Surgery should be reserved for patients who either have failed medical management or have complications from BPH, such as recurrent urinary tract infections, refractory urinary retention, bladder stones, or renal insufficiency as a result of obstructive uropathy.</abstract><cop>United States</cop><pub>Annual Reviews</pub><pmid>26331999</pmid><doi>10.1146/annurev-med-063014-123902</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4219 |
| ispartof | Annual review of medicine, 2016-01, Vol.67 (1), p.137-151 |
| issn | 0066-4219 1545-326X |
| language | eng |
| recordid | cdi_pubmed_primary_26331999 |
| source | Annual Reviews Complete A-Z List; MEDLINE |
| subjects | 5-alpha reductase inhibitors 5-alpha Reductase Inhibitors - therapeutic use Ablation Techniques adrenergic alpha-antagonists Adrenergic alpha-Antagonists - therapeutic use Digital Rectal Examination Family medical history Humans Inflammation Laser Therapy lower urinary tract symptoms Lower Urinary Tract Symptoms - etiology Male Medical diagnosis Phosphodiesterase 5 Inhibitors - therapeutic use phosphodiesterase type 5 inhibitors Prostatic Hyperplasia - complications Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - metabolism Prostatic Hyperplasia - pathology Prostatic Hyperplasia - therapy Transurethral Resection of Prostate Urinalysis Urinary tract diseases Watchful Waiting |
| title | Management of Benign Prostatic Hyperplasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T04%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Benign%20Prostatic%20Hyperplasia&rft.jtitle=Annual%20review%20of%20medicine&rft.au=Kim,%20Eric%20H&rft.date=2016-01-01&rft.volume=67&rft.issue=1&rft.spage=137&rft.epage=151&rft.pages=137-151&rft.issn=0066-4219&rft.eissn=1545-326X&rft_id=info:doi/10.1146/annurev-med-063014-123902&rft_dat=%3Cproquest_pubme%3E3967386571%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1768905753&rft_id=info:pmid/26331999&rfr_iscdi=true |